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Abstract
Introduction: Common mental disorders (CMDs) particularly depression and anxiety, are highly comorbid with HIV also in
young people living with HIV (YLWH). In sub-Saharan Africa (SSA) where most YLWH reside, there are limited summary data
on CMDs among these youths, yet there are previous systematic reviews summarizing data on CMDs among adults living with
HIV. We conducted a systematic literature review on the prevalence and correlates of CMDs among YLWH, aged 10 to
24 years, from SSA.
Methods: We searched African Index Medicus, African Journals Online and five other electronic databases (from database
inception up to 31 December 2020) for relevant studies published in English. The key search terms applied were as follows:
“Depression OR Anxiety”, “Young people”, “HIV infections” and “sub-Saharan Africa”.
Results and discussion: Out of 3989 articles, 31 studies were included in the review. The prevalence of CMDs in YLWH
widely varied ranging between 16.0% and 40.8% for major depression, 4.4% and 52.6% for depressive symptoms and 2.2%
and 25.0% for anxiety symptoms. Anxiety disorder was estimated at 45.6%. Four of the five included studies with a comparison group of HIV-negative young people reported significantly higher prevalence estimates of depressive disorders among
YLWH. Several sociodemographic, psychosocial and HIV-related correlates of CMDs were reported but most lacked consensus
across studies. Nevertheless, female sex, older age, fewer schooling years, HIV-positive status, bullying, sexual abuse, HIV-related stigma, social support and poor antiretroviral therapy adherence were frequently reported (in ≥2 studies) as significant
correlates of depressive symptoms among YLWH. Higher social support was the only frequent significant correlate of anxiety
symptoms.
Conclusions: The burden of CMDs among YLWH from SSA is substantial and appears to be significantly higher when compared with HIV-negative peers, particularly for depressive disorders. However, more comparative research is needed. Importantly, screening for CMDs at the youth HIV-clinics should be prioritized especially for YLWH at high risk of CMDs, to
facilitate early management or referral for treatment. Furthermore, youth-friendly psychological interventions addressing
CMDs in YLWH should urgently be piloted in SSA, incorporating contextual components that may directly or indirectly reduce
symptoms of CMDs among YLWH, such as social support.
Keywords: young people; HIV infections; depression; anxiety; correlates; sub-Saharan Africa

Additional Supporting information may be found online in the Supporting Information tab for this article.
Received 12 October 2020; Accepted 23 March 2021
Copyright © 2021 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium,
provided the original work is properly cited.

1 | INTRODUCTION
Globally, there are over 1.8 billion young people aged 10 to
24 years, the majority residing in low- and middle-income
countries [1]. The term “young people” generally combines the
overlapping terms of “adolescents,” that is individuals in the

10- to 19-year age group and “youths,” that is the 15- to 24year age group [2] and will be used to refer to both age
groups in this work. Young people represent a significant proportion of people living with HIV. As of 2018, 1.6 million
young people aged 10 to 19 years were living with HIV globally [3], whereas 3.9 million young people aged 15 to 24 years
58
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lived with HIV worldwide by 2014 [4]. Most of these young
people were infected through vertical transmission and live in
sub-Saharan Africa (SSA) [5,6].
Common mental disorders (CMDs), herein referring to
depressive and anxiety disorders or their symptoms, are very
frequent in people living with HIV [7-9] and the risk is two to
three times higher than the general population [10]. Among
young people living with HIV (YLWH), global reviews [5,11,12]
report the prevalence of comorbid CMDs as high as 44.0%
for depressive disorders and 48.2% for anxiety disorders. In
recent reviews on the burden of psychiatric disorders among
YLWH aged 10 to 19 years in SSA [13,14], depressive and
anxiety symptoms ranged from 14% to 53% and 15% to 25%
respectively. The burden of CMDs may also be higher in
YLWH than their peers without HIV [15] or even other vulnerable groups of young people, such as those in juvenile
detention [16]. The higher risk of CMDs in people living with
HIV, including the youth, may be caused by side effects of
antiretroviral therapy (ART) [17,18], persistent HIV-related
stigma in the community [19,20], the direct and indirect neurologic effects of HIV on the brain [21] and the fear of premature death [22]. There are detrimental consequences when
CMDs co-occur with HIV including worsened prognosis of
HIV infection [23], increased risk of suicidality [24], non-adherence to ART [25], poor quality of life [26] and alteration of
economic productivity of people living with HIV [23].
Previous global reviews [5,11,12] and one recent review
from SSA [13] have reported on factors associated with
CMDs among YLWH, but there is little or no consensus
across individual studies included in these reviews. Notably,
most of the studies included in the global reviews have been
conducted in Western countries (Europe and North America).
Only four out of the 14 studies included in the review from
SSA reported a few correlates of CMDs. Nevertheless, female
sex [16,27], older age [28-30], poor adherence to ART [31,32],
stressful life events [33,34], parental or caregiver mental
health status [15,27,35], maternal HIV-positive status [15,29],
low cluster of differentiation-4 (CD4) cell count [27,36] and
history of AIDS-defining illness [36,37] appear important correlates of CMDs in YLWH as they are reported by more than
one study in the aforementioned reviews. Extrapolating findings from especially reviews of global nature to inform interventions seeking to address the mental health of YLWH from
settings such as SSA may be problematic because of contextual differences (especially where very few of the studies
included are from the setting targeted for intervention). With
the increasing research effort towards an understanding of
the mental health of people living with HIV from SSA [38],
including the youth [39-41], there is a need for a greater
understanding of context-specific factors associated with
CMDs among people living with HIV from this setting.
The increasing mental health issues among YLWH is an
emerging public health concern with the potential of burdening the already busy healthcare systems and the scarce human
resources in mental healthcare in resource-limited settings like
those of SSA [7,23]. Hitherto, no study has extensively summarized data on the burden and contextual determinants of
CMDs among YLWH from SSA, a region where most of these
HIV-positive young people reside. While there have been several global reviews trying to understand the burden of mental
health problems among YLWH [5,11,12], most of the studies

included have been conducted outside SSA, limiting the generalizability of their findings to the African context. Past systematic reviews on the burden of CMDs among people living with
HIV from SSA [9,38,42] have only considered studies recruiting adults living with HIV sidelining YLWH who currently represent a considerable percentage of people living with HIV.
The recent systematic reviews involving YLWH from SSA
[13,14] are limited to young people aged 10 to 19 years only
and broadly focus on many psychiatric disorders. For the current systematic review, the overall objective was to summarize the available evidence on the prevalence and factors
associated with CMDs among YLWH aged 10 to 24 years
from SSA. The specific objectives of this review were:
1 To systematically summarize the existing literature on the
prevalence of CMDs, specifically depressive and anxiety
disorders, or their symptoms, among YLWH aged 10 to
24 years from SSA alongside information on measurement
tools used and their contextual reliability and/or validity.
2 To systematically identify the factors associated with
CMDs, specifically depressive and anxiety disorders or
their symptoms, among YLWH aged 10 to 24 years from
SSA.
The added value of this review is two-fold. First, by extending the review age range, we include young people regarded
as adults (societally and/or by law) who are expected to take
care of themselves, most often outside the family context,
with implications for an arrangement of mental health support.
Second, although the recent reviews from SSA give important
information on the prevalence and range of mental disorders
in YLWH, the review by Olashore et al. [14] only addresses
the association of these disorders with ART adherence. In
both reviews [13,14], their approach limits the possibility to
understand which contextual factors importantly relate to
CMDs, the most frequent of the psychiatric disorders. This
review addresses this gap.

2 | METHODS
2.1 | Search strategy
The Preferred Reporting Items for Systematic Review and
Meta-analysis (PRISMA) guidelines [43] informed the design
and reporting of this systematic review. The study protocol
was registered with the International Prospective Register of
Systematic Reviews (PROSPERO) under registration number
CRD42020160806. Structured electronic searches were initially conducted in African Index Medicus, African Journals
Online, Google Scholar, PsycArticles, PsycInfo, PubMed and
Web of Science Core collection databases between 3 and 24
December 2019. The search was later updated in January
2021 to capture publications up to 31st December 2020.
Where applicable, databases were searched from the time of
their inception. The key search terms included “Depression/
Anxiety”, “Young people”, “HIV infections” and “sub-Saharan
Africa” which were combined by the Boolean operator “AND”.
Synonyms for each of the key search terms were combined
using the “OR” Boolean operator. Where applicable, Medical
Subject Headings (MeSH) terms were used. (Additional file
S1) provides the search string used in the PubMed database,
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which was modified to meet the specifications for other databases.
The search was restricted to studies published in the English language, where a database could allow this filter. All the
retrieved references were exported and managed in EndNote
version 7. An additional search for relevant articles was conducted by scanning the reference lists of included articles and
any relevant systematic reviews captured in the initial search.

2.2 | Screening of articles by inclusion and
exclusion criteria
For potential inclusion, all the articles returned from the database searches were screened in two steps: i) based on title
and abstract and ii) by full text. The first author (ET) screened
the articles for eligibility. To reduce bias that may arise from
human error, two other reviewers (CN and MKN) independently repeated 10% of the study screening at every stage
through a systematic random selection of articles divided into
two halves, each for the independent reviewers. Rates of
agreement between each of the independent reviewers and
the first reviewer were consistently high, and minor disagreements were settled through consensus. To be included for
review, studies had to fulfil a pre-determined inclusion and
exclusion criteria as shown in Table 1.

2.3 | Data extraction
ET and MKN independently extracted the following data from
included studies using a standardized Microsoft Excel data
abstraction form: (i) Article details – name of the first author,
title and publication year; (ii) Study details – country of origin,
study design, study setting, data collection period and
response rate (where reported) and the reported study limitations; (iii) Study participant characteristics – HIV-related data
(mode of acquisition, time since diagnosis, ART regimen and
duration on ART treatment), sample size, sampling method,
source of the sample, age (mean, median, or range) and sex
(proportion of male vs. female); (iv) Outcome and measures –
prevalence of depression and anxiety, or their symptoms, measurement tool used, cut off score applied (for screening tools),
information on local tool validation, factors associated with
depression and anxiety or their symptoms (alongside the
reported measure of effect and precision estimate).

Table 1. Study selection criteria
Inclusion criteria

Exclusion criteria

Population
- Studies with HIV-positive
young people from SSA.
- Studies with participants

- Studies involving HIV-positive
young people outside SSA.
- Studies involving HIV-negative

aged 10 to 24 years or with

young people or with HIV-

mean/median age within this

positive participants outside

age bracket.

the 10 to 24 age range.
- Studies with unspecified age
range, mean or median age of
participants.
- Studies with very specific
subpopulations of young
people e.g. pregnant women,
out-of-school adolescents et
cetera.

Outcome
- Studies on depression or
depressive symptoms and
associated factors.
- Studies on anxiety disorder

- Studies on mental disorders
other than depression or
anxiety, or their symptoms.
- Studies using measurement

or anxiety symptoms and

scales evaluating both anxiety

associated factors.

and depression without
providing separate data.
- Studies where reported
measurement scales do not
evaluate depression or anxiety,
or their symptoms.

Study designs
- Cross-sectional studies
- Case-control studies
- Cohort studies

- Review articles e.g. narrative,
systematic, scoping
- Intervention studies
- Case studies/reviews
- Commentaries or editorials
- Conference proceedings,
symposia abstracts, or
workshop publications
- Qualitative studies
- Books or book sections

2.4 | Quality assessment
ET and MKN independently assessed the risk of bias of each
included study using the Newcastle–Ottawa Scale [44]. These
authors then held a meeting to resolve any disagreements in
quality rating. Using this tool, studies were assessed based on
three domains: the selection of participants, comparability of
study groups and the ascertainment of exposure (for case–
control studies) or outcome of interest (for cohort and crosssectional studies). A star-grading system was used, with each
domain item receiving one or two stars if appropriate methods were reported. A maximum of nine stars was awarded for
cohort and case–control studies, and a maximum of 10 stars
for cross-sectional studies. Studies were classified as unsatisfactory, satisfactory, good and very good if they had a total of
0 to 4, 5 to 6, 7 to 8 and 9 to 10 stars respectively.

- Theses and dissertations
Studies with a comparison group of HIV-negative young people and
providing disaggregated mental health data by HIV infection status
were included. Studies duplicating similar project data to an already
included main and more comprehensive article were excluded. SSA,
sub‐Saharan Africa.

2.5 | Data analysis
Because of the heterogeneous nature of measurement tools
used across included studies, data were narratively summarized. Data on the prevalence of CMDs among YLWH were
summarized by each homogeneous measurement tool used,
whereas data on correlates of CMDs were summarized by
the investigated outcome (depression or anxiety). We manually
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Too EK et al. Journal of the International AIDS Society 2021, 24(S2):e25705
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25705/full | https://doi.org/10.1002/jia2.25705

calculated the odds ratio using the reported proportions from
individual studies comparing the prevalence of CMDs between
YLWH and their HIV-negative peers. In this review, only factors significantly associated with either depression or anxiety,
or their symptoms at p < 0.05 in the multivariable analysis
were considered and extracted as correlates. Basic descriptive
statistics (frequencies with percentages) were used to summarize data on the region of SSA where each of the included
studies was conducted.

and ART-use status (ART na€ıve vs. ART experienced) [38] may
influence their mental health experiences. In this review, none
of the studies recruiting a mix of participants provided disaggregated mental health data by any of these characteristics.
An in-depth investigation of this nature in the African context
will require researchers working with a mixed sample of
YLWH to collect and profile disaggregated mental health data
by, for example mode of HIV infection or ART-use status.
Additional data on CMDs among YLWH residing in rural settings of SSA are also needed, so far, research focus has been
biased towards urban settings.

3 | RESULTS AND DISCUSSION
The electronic search yielded 3988 hits from the different
databases (African Index Medicus, n = 11, African Journals
Online, n = 147, Google Scholar, n = 2137, PsycArticles,
n = 8, PsycInfo, n = 865, PubMed, n = 302 and Web of
Science, n = 518). A scan of the reference lists of included
articles and relevant systematic reviews captured by the
search yielded one additional article. After removing duplicates and screening articles based on the eligibility criteria,
we included 31 studies in the review. Figure 1 shows the
PRISMA flowchart for the systematic review process.

3.1 | Characteristics of included studies
(Additional file S2) presents in detail the characteristics of the
31 included studies. The reviewed studies were mostly conducted in Eastern (n = 13; 41.9%) or Southern (n = 13;
41.9%) African countries except four studies [45-48] that
were conducted in a Western African country (12.9%) and
one study (3.2%) from Central Africa [49]. The included studies enrolled a total of 9935 YLWH (individual study sample
size ranging from 58 to 1088). Additionally, the studies with a
comparison group enrolled 1000 HIV-negative young people
(individual study sample size ranging from 44 to 600).
Many of the studies (n = 29) were cross-sectional in design
and published after 2010, except two studies [47,50]. A
review of the literature on depression among HIV-positive
adults from SSA [38] also observed that most of the studies
included were conducted after 2010. It is, therefore, encouraging to note that from the beginning of the last decade,
there is an upsurge of research work towards an understanding of the mental health of people living with HIV in Africa
with the potential to inform clinical practice and policy.
Many of the studies were conducted in urban settings of
SSA (n = 20). Nearly all studies (n = 29) recruited YLWH
from HIV-specialized clinics except one study [51] that
recruited from the community. In one study [52], this information could not be retrieved because the study was only available in abstract form (see study quality section for details).
YLWH were exclusively on ART in most studies (n = 17). Eight
studies [46,53-59] recruited ART experienced (majority) and
ART na€ıve participants, whereas six studies [45,48,60-63] did
not provide information on participant ART-use status. In
eight studies [52,55,59,61,64-67] YLWH were exclusively perinatally HIV-infected. Five studies [45,49,58,68,69] had a mixture of perinatally and behaviourally HIV-acquired youths; the
rest (18 studies) did not provide information on the mode of
HIV infection. Outside Africa, certain characteristics of YLWH
like mode of HIV infection (behavioural vs. perinatal) [8,70]

3.2 | Measurement tools for CMDs, their reliability
and validity among YLWH from SSA
CMDs in YLWH from SSA were assessed using both diagnostic tools and symptom screeners. Diagnostic tools used in this
study included the Mini-International Neuropsychiatric Interview for children and adolescents (MINI-KID) [71] used in
three studies [45,46,64] to diagnose major depression and the
tenth revision of the International Classification of Diseases
(ICD-10) symptom checklist [72] used by Musisi and Kinyanda
[50] to diagnose major depression and anxiety disorder. The
other studies used different types of CMD symptom screeners. Kinyanda et al. [55] used the 5th edition of the Diagnostic
and Statistical Manual (DSM) of mental disorders referenced
Child and Adolescent Symptom Inventory-5 (CASI-5) [73] and
the fourth revision of the Youth Inventory (YI-4R) [74] to
assess symptoms of major depression, any anxiety disorder,
generalized anxiety disorder, social and separation anxiety disorders. Buckley et al. [65] used the DSM (4th edition) referenced 84-item Patient Health Questionnaire for Adolescents
(PHQ-A) [75] to assess symptoms of major depression and
anxiety disorder (specifically panic disorder). Various screening
tools based on different cut-off scores were also used to measure depressive (Table 2) or anxiety symptoms (Table 3).
These screening tools included the 9-item patient health questionnaire [76] used in six studies [49,53,57,60,77, 78], the
centre for epidemiologic studies depression scale [79] used in
four studies [51,54,56,62], the child depression inventory [80]
used in four studies [58,59,81,82], Beck’s depression inventory [83] used in three studies [48,61,84], the revised children’s depression rating scale [85] used by Kim et al. [28], the
hospital anxiety and depression scale [86] used by Sale &
Gadanya [47], Reynold’s adolescent depression Scale [87]
used by Paul et al. [63], National Institute of Health toolbox –
Sadness module [88] used by Molinaro et al. [52], the Beck’s
youth inventory [89] used in two studies [66,67] and the
revised children’s manifest anxiety scale [90] used in two studies [58,59]. Most studies did not report information on the
reliability and/or validity of these measurement tools among
YLWH. In some studies, where this information was not provided, authors pointed out that the tool they used was previously validated in the study country or provided a reference
to the tool validation process (see Tables 2 and 3). Where
reported, information on tool reliability and/or validity was
mostly limited to Cronbach’s alpha, a measure of internal consistency of a scale, and values were above the acceptable
threshold of 0.7.
For any meaningful epidemiological data that can inform
appropriate interventions, there is a need for future studies
61
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Records iden ﬁed through
database searching
(n = 3988)

Addi onal records iden ﬁed
through other sources
(n = 1)

Screening

Records a er duplicates removed
(n = 3201)

Records screened
(n = 3202)

Eligibility

Full-text ar cles assessed
for eligibility
(n = 221)

Included

Studies included in
qualita ve synthesis
(n = 31)

Studies repor ng both
prevalence and
correlates of CMDs
(n = 18)

Studies repor ng
only the prevalence
of CMDs
(n = 11)

Records excluded by tle and abstract
(n = 2981)

Full-text ar cles excluded, with reasons
(n = 190)
Data not disaggregated by HIV status, n=3
Lack primary outcome data, n=9
Unspeciﬁed age range/mean/median, n=3
No CMDs measurement tool used, n=4
Studies from similar project, n=5
Not about CMDs, n=5
Not HIV related, n=23
Review ar cles, n=8
Qualita ve study, n=3
Not from sub-Saharan Africa, n=7
Adults over 24 years, n=114
Children under 10 years, n=4
Systema c review, n=1
Full-text unavailable, n=1

Studies repor ng only
the correlates of
CMDs
(n = 2)

Figure 1. PRISMA flowchart for the systematic review process. CMDs, common mental disorders.

involving YLWH in SSA to measure CMDs using culturally
appropriate and locally validated tools. Where feasible, validated mental health diagnostic measures should be administered concurrently to check the diagnostic accuracy of these
mental health screening tools.

3.3 | Prevalence of CMDs among YLWH from SSA
Twenty-nine studies reported the prevalence of either major
depression or depressive symptoms [45-67,77,78,81]. Of
these, seven studies [50,55,58,59,65,66,78] additionally
reported the prevalence of anxiety or its symptoms. No study
investigated the prevalence of anxiety or its symptoms as a
stand-alone mental disorder among YLWH. Tables 2 and 3
present the prevalence of depressive and anxiety disorders
(or their symptoms according to the screening tool used), as
reported from the above studies.
In summary, wide-ranging prevalence estimates of CMDs
were reported among YLWH. The prevalence of major depression ranged between 16.0% and 40.8% [45,46,50,64]. A

prevalence of 5.2% for symptoms of major depression was
reported by a Ugandan study [55]. When comparing YLWH
and their HIV-negative peers [65], the observed prevalence of
symptoms of major depression was 6.2% and 7.4% respectively. Regardless of the screening tool used, depressive symptoms ranged between 4.4% and 52.6%. The prevalence of
anxiety disorder among YLWH from Uganda was 45.6% [50].
When comparing YLWH and their HIV-negative peers [65],
the observed prevalence of symptoms of panic disorder was
3.7% and 2.5% respectively. Regardless of the screening tool
used, anxiety symptoms ranged between 2.2% and 25.0%.
Wide-ranging CMD prevalence estimates have been documented in past reviews involving YLWH [11,12,91] but also
adults living with HIV in SSA [9,38]. Differences in study context and population (like the conceptualization of mental
health issues, exposure levels to triggers of mental health
problems), study respondents (self vs. others) and use of
heterogenous measurement tools (including different cut-off
scores for similar measures) may contribute to the wide variation of the reported prevalence estimates. As a start point for
62

Country

Outcome of interest

Sample size (n)

Uganda

Nigeria

Ashaba et al., 2018 [64]

Bankole et al., 2017 [46]

Major Depression

Major Depression

Major Depression

Uganda

Major Depression

82

75 HIV+
75 HIV

224

201

Uganda

Symptoms of Major Depression

Tanzania

Ramos et al., 2018 [57]

Depressive symptoms
Depressive symptoms

270
1088

135

Filiatreau et al., 2020 [62]

South Africa

Depressive symptoms

334

193

Kenya
South Africa

Gaitho et al., 2018 [77]
Haas et al., 2020 [78]

Depressive symptoms

182
479

The centre for epidemiologic studies depression scale (CES-D)
Fawzi et al., 2016 [51]
Rwanda
Depressive symptoms

DRC

Ekat et al., 2020 [49]

Depressive symptoms
Depressive symptoms

280

Kenya

81 HIV

81 HIV+

479

Depressive symptoms

Tanzania

Dow et al., 2016 [53]

Dyer et al., 2020 [60]

The 9-item patient health questionnaire (PHQ-9)

The patient health questionnaire for adolescents (PHQ-A)
Buckley et al., 2020 [65]
South Africa Symptoms of Major Depression

Kinyanda et al., 2019 [55]

The youth inventory fourth revision (YI-4R) and the child and adolescent symptom inventory-5 (CASI-5)

Musisi & Kinyanda, 2009 [50]

International classification of diseases, tenth edition (ICD-10) symptom checklist

Nigeria

Adeyemo et al., 2020 [45]

The mini-international neuropsychiatric interview for children and adolescents (MINI-KID)

Author, year

YI-4R

CES-D

CES-D

PHQ-9

PHQ-9
PHQ-9

PHQ-9

PHQ-9

PHQ-9

PHQ-A

CASI-5

20.0% among HIV+
6.7% among HIV

NR
NR
NR
NR

≥9
≥1
≥10
≥10

≥16

Cronbach alpha of 0.76

validated in Rwanda

they used a CES-D previously

However, the authors note that

Not provided in this study.

NR

≥30

NR
≥5

NR

of 0.17, p < 0.01

test–retest reliability

Cronbach alpha of 0.77 and

of 0.2, p < 0.01

and test–retest reliability

Cronbach alpha of 0.88

–

16.0%

–

27.5%

26.0%

20.4%

52.6%
4.4%

38.5%

10.0%

12.1%

(Continued)

p = 0.99

7.4% among HIV

6.2% among HIV+

5.2%

40.8%

p = 0.01

16.9%

estimates

Prevalence

–

tool validation

Information on local

–

≥10

NR

NR

NA

NA

MINI-KID

ICD-10

NA

NA

score

Cut-off

MINI-KID

MINI-KID

tool used

Assessment

Table 2. Prevalence estimates for major depression and depressive symptoms among YLWH from SSA according to the measurement tool used
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Zambia

Uganda

South Africa

South Africa

Cavazos-Rehg et al., 2020 [81]

West et al., 2018 [58]

Woollett et al., 2017 [59]

South Africa

Nigeria

Earnshaw et al., 2018 [61]

Yarhere & Jaja, 2020 [48]

562

The revised children’s depression rating scale (CDRS-R)
Kim et al., 2015 [28]
Malawi
Depressive symptoms

44 HIV

204 HIV+

58

250

507

343

278

675

600 HIV

300 HIV+

190

336

Sample size (n)

475

Rwanda

Kikuchi et al., 2017 [67]

Depressive symptoms

Depressive symptoms

Depressive symptoms

Depressive symptoms

Depressive symptoms

Depressive symptoms

Depressive symptoms

Depressive symptoms

Depressive symptoms

Depressive symptoms

Outcome of interest

Depressive symptoms

South Africa

Hoare et al., 2019 [66]

Beck’s youth inventory-II (BYI-II)

Ethiopia

Abebe et al., 2019 [84]

Beck’s depression inventory-II (BDI-II)

Tanzania

Lwidiko et al., 2018 [82]

The child depression inventory

Uganda

Okawa et al., 2018 [56]

Country

Kemigisha et al., 2019 [54]

Author, year

Table 2. (Continued)

CDRS-R

inventory)

BYI-II (Depression

inventory)
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possible quantification of the magnitude of CMDs among
YLWH in SSA, researchers, perhaps from similar regions,
should work towards the use of homogenous mental health
measurement tools.
Compared to HIV-negative peers, YLWH from SSA appear
to be experiencing higher CMDs, particularly depressive disorders. However, the evidence is limited to draw any conclusions. Only five studies in this review [46,52,65,66,82]
compared CMDs between YLWH and their HIV-negative
peers. Four of these studies reported significantly higher
prevalence estimates of either major depression [46] or
depressive symptoms [52,66,82] among YLWH (Table 2). In
these studies, YLWH were 3.5- [46], 2.9- [66], 6.0- [82] and
2.1-times [52] more likely to have higher depression compared to their HIV-negative peers. Even though the odds of
symptoms of major depression were 17% less likely among
YLWH compared to HIV-negative peers in the fifth study [65],
there was no significant between-group difference (Table 2).
In the literature, individual empirical studies from other settings comparing for instance depressive symptoms among
YLWH and their HIV-negative peers report mixed results.
Some observe significant group differences [92], whereas
others observe insignificant differences [27,93].
For anxiety, two of the five studies above [65,66] also compared the prevalence of anxiety symptoms between YLWH
and their HIV-negative peers and reported slightly higher, but
statistically insignificant, prevalence estimates among YLWH
(Table 3). In these studies, even though insignificant, the odds
of anxiety symptoms were 1.5 [65] and 1.3 times [66] higher
in YLWH. In contrast, a study from Italy found significantly
higher anxiety scores among YLWH compared to their HIVnegative peers [92]. For a clearer insight as to whether YLWH
from SSA are at an elevated risk of CMDs compared to their
HIV-negative peers, there is a need for more comparative
research.
Despite the observed wide-ranging prevalence estimates,
this review generally shows that the burden of CMDs among
YLWH from SSA is high, and that rates may be two to six
times higher when compared with HIV-negative youths, particularly for depressive disorders. However, caution must be
taken when interpreting the reported prevalence estimates.
Only four studies [45,46,50,64] used a mental health diagnostic interview based on either DSM or ICD criteria. Two studies [55,65] used DSM-referenced checklists to assess
symptoms of major depression and an anxiety disorder. The
rest collected mental health data of YLWH using screening
tools, some with unknown reliability and/or validity. Most
importantly, screening and early management or referral for
treatment of CMDs among YLWH from SSA are urgently
needed at the HIV clinics servicing these youths, more so
because CMDs co-occurring with HIV are associated with
worse HIV outcomes [23,25].
Overall, fewer studies in this review focussed on anxiety
compared to depression. This under-investigation of anxiety
disorders is of concern because previous research involving
YLWH report higher rates of anxiety than depression [94].
Partly, the under-investigation could be due to the paucity of
adequately validated measurement tools of anxiety [95]. To
allow more research focus on anxiety among YLWH in the
African context, as has depression, there is a need for adequate validation of measurement tools for anxiety, taking into
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consideration contextual and cultural differences within the
SSA setting.

3.4 | Correlates of CMDs among YLWH from SSA
To the best of our knowledge, this is the first review from
SSA to comprehensively collate information about factors
associated with CMDs in YLWH. Recent reviews from SSA
involving YLWH provide an overview of some of these factors
because of broadly covering multiple psychiatric disorders
[13,14], focussing on only one correlate – ART adherence [14]
or including HIV-positive young people up to 19 years only
[13,14]. In this review, 19 studies reported the correlates of
either major depression [64], symptoms of major depression
[65]
or
depressive
symptoms
among
YLWH
[28,48,49,53,54,56,58,61,62,66,67,69,77,78,81,82,84]. Of these,
four studies concurrently investigated correlates of anxiety
symptoms [58,66,69,78]. One study [68] independently focused
on the correlates of anxiety symptoms. There was limited consensus across studies for most of the reported correlates. Generally, the factors reported to be significantly associated with
CMDs among YLWH from these studies can be categorized into
sociodemographic, psychosocial and HIV-related clinical correlates and are presented as such in this paper.

3.5 | Correlates of major depression or depressive
symptoms among YLWH from SSA
Table 4 presents in detail the identified correlates of major
depression or depressive symptoms among YLWH as reported
from the studies above. In summary, none of the studies
reported any sociodemographic correlate of major depression.
The sociodemographic factors that significantly increased the
risk for higher depressive symptoms among YLWH included:
older age [49,53,69,77,84], female sex [28,53], fewer schooling
years [28,49], longer distance to the clinic [54], and HIV-positive status [66,82]. Similarly, but in the inverse direction, Haas
et al. [78] report younger age as significantly lowering the risk
for depressive symptoms. There appeared to be a consensus
between two or more studies regarding older age, female sex,
fewer schooling years and HIV-positive status as significant
sociodemographic correlates of higher depressive symptoms,
congruent with results from previous reviews involving YLWH
[5,11, 12]. In contrast, one included study [81] reported older
youth age as protective against depressive symptoms and
male sex as a risk indicator for higher depressive symptoms.
Better overall health [69], residing in rural areas [82], not
being in a romantic relationship [28], not failing a term or
class [28] and higher height for age z-scores [67] were the
sociodemographic factors that significantly decreased the risk
for depressive symptoms. However, there was a lack of consensus across studies for these correlates.
Females living with HIV from SSA could be at a higher risk
of depressive symptoms because of additional experiences of
traumatic events such as sexual abuse and intimate partner
violence, some of which may have had a role in their acquisition of HIV infection [96,97]. Additionally, they are more likely
to be stigmatized [98] and blamed for HIV transmission within
families in patriarchal societies like those of SSA [99]. Older
YLWH compared to younger ones are more likely to understand the threat posed by HIV infection to their own life [16],

which may manifest as depressive symptoms. The awareness
of HIV-related cognitive deficits [41] by a YLWH manifesting
in ways like grade retention or poor performance may explain
the association between fewer years of schooling and higher
depressive symptoms. Although two studies in this review
observed significant associations between HIV-positive status
and higher depressive symptoms, Western empirical studies
report non-significant associations [27,93]. In SSA where poverty is high [100], HIV-related adjustments such as recommended intake of a balanced diet with ART use and meeting
the regular transportation costs for clinic appointments may
be additional challenges to most families of YLWH. Such challenges may lead to psychiatric manifestations among YLWH.
Bullying was the only reported psychosocial correlate of
major depression in the study examining the relationship
between psychosocial factors and major depression [64]. Psychosocial factors that significantly increased the risk for higher
symptoms of major depression among YLWH included living
with someone who has anger/aggression problems and ever
witnessing violence at home [65]. Psychosocial factors that
significantly increased the risk for higher depressive symptoms among YLWH were as follows: bullying victimization
[69], bullying for taking ART [28], caregiver depression [67],
grandparent as primary caregiver [81], low social support [84],
HIV-related stigma in its various forms such as perceived
stigma [53,56,66,84], internalized stigma [61,69] and associative stigma [61], history of sexual [62,69], emotional [69] and
physical abuse [62] or a combination of physical and/or sexual
abuse [62], conflict in the household [78], unsatisfactory relationship with family or health workers [56], insomnia and suicidal ideation [48], negative clinic interactions [69], history of
childhood deprivation [82] and stressful life events [66]. On
the other hand, the following psychosocial factors significantly
lowered the risk for depressive symptoms in YLWH: access to
a clinic support group [69], positive parenting [69], higher
socio-economic status [81], family cohesion [81], not being
bereaved in the family [28], self-efficacy [69], satisfaction with
physical appearance [28] and higher social support [58,69,81].
Among the reported psychosocial correlates of depressive disorders in YLWH, bullying, HIV-related stigma, history of sexual
abuse and social support were consistently reported across
two or more studies as significantly associated with depressive disorders, similar to previous review findings [5,11,12].
The negative effects of HIV-related stigma among YLWH
including social devaluation and experience of injustices like
restrictions in interacting with other people and being denied
equal opportunities of enrolling or staying in school [20], may
explain why HIV-related stigma (in its various forms) is associated with higher depressive symptoms in YLWH. HIV-related
stigma can lead to depression manifesting as low self-worth,
self-isolation, loss of hope in future plans or aspirations and
poor ART adherence [20,84,101]. As previously emphasized
[19,20], there is a need for continuously addressing HIV-related stigma in multiple settings within the community. Bullying can lead to negative outcomes such as humiliation, selfblame and shame [102] and coupled with living with HIV at a
younger age, high levels of depressive symptomatology may
be expected among YLWH. The finding that higher social support is associated with fewer depressive symptoms (or vice
versa, low social support being associated with more depressive symptoms) supports the proposition of a buffering effect
66
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of social support against psychological distress as described in
the “buffering hypothesis” [103]. This hypothesis postulates
that any form of social support (social companionship, emotional, informational, or instrumental support) proffers protection to individuals facing stressful life events (in this case, HIV
infection adversity) and assists them in coping with distress.
The persistent psychological distress among sexually abused
YLWH can be addressed through continued counselling and
appropriate support mechanisms.
The following HIV-related clinical factors significantly
increased the risk for elevated depressive symptoms among
YLWH: poor adherence to ART [49,53,77,84], history of opportunistic infections [84], experiencing ART side effects [69] and
taking efavirenz-based ART [67]. On the other hand, better
immunological stage [28] or increasing CD4 cell count [48]
were associated with fewer depressive symptoms among
YLWH. See Table 4 for effect sizes reported from individual
studies. Of these correlates, only poor adherence to ART was
consistently reported across four studies, a finding that has
also been observed in past global reviews involving YLWH
[5,11,12]. Non-optimal adherence to ART can lead to viral nonsuppression [104], and patients may experience psychological
distress when informed of a poor prognosis. This may explain
the observed consistent significant association between poor
ART adherence and elevated depressive symptoms among
YLWH from SSA [49,53,77,84]. However, depression can also
be an antecedent to poor ART adherence [25], thus there is
uncertainty on the temporality of the significant associations
reported in the above four cross-sectional studies.

3.6 | Correlates of anxiety symptoms among YLWH
from SSA
Table 5 presents in detail the identified correlates of anxiety
symptoms among YLWH. The study that diagnosed anxiety
disorder [50] did not report any correlation. Younger age [78]
and better overall health among YLWH [69] were the only significant sociodemographic correlates of anxiety symptoms. The
following psychosocial factors significantly increased the risk
for anxiety symptoms among YLWH: internalized stigma [69],
anticipated stigma [69], history of sexual abuse or emotional
abuse in the past year [69], bullying victimization [69], poor
parental monitoring [69], history of physical violence [78] and
stressful life events [66]. Conversely, higher social support
[58,68], self-efficacy [69], positive parenting [69] and access
to a clinic support group [69] were the factors that significantly decreased the risk for anxiety symptoms among YLWH
from SSA. Experiencing ART side effects was the only significant HIV-related clinical correlate of anxiety symptoms among
YLWH reported by one South African study [69].
Similar to what was observed for depressive symptoms,
social support was also a significant correlate of anxiety symptoms reported across two studies [58,68]. As earlier noted,
social support may also provide a buffering effect against anxiety symptoms [103].

3.7 | Quality of included studies
(Additional file S3) shows the quality scores of included studies according to their study designs, based on the NewcastleOttawa risk of bias assessment tool. Two studies were graded

to be of very good quality [55,69], twelve of good quality
[28,53,54,58,64-67,77,78,82,84], nine of satisfactory quality
[45,49-51,56,61,62,68,81] and seven of unsatisfactory quality
[46-48,57,59,60,63]. One study [52], available only as an
abstract publication, provided relevant mental health data for
this review. This study was rated as unclear of high risk of bias
because of a lack of feedback from authors when contacted
(on three attempts) with a request for data that would enable
assessment of the quality of the entire study.
Even though most of the studies reporting on correlates of
CMDs among YLWH were of low risk of bias, they were
cross-sectional in design. This study design limits inferences
on causality. Therefore, the summarized significant correlates
of CMDs among YLWH in this review should be interpreted
with caution. For better decisions on priority intervention
areas, future studies from this setting should seek to substantiate the causal direction of the identified correlates, using, for
instance longitudinal study designs.

3.8 | Study limitations
This review has several limitations worth highlighting. First,
the review does not provide pooled prevalence estimates of
CMDs among YLWH from SSA because measurement tools
used across studies were highly heterogeneous. Relatedly,
because a meta-analysis could not be performed, we are
unable to report on publication bias. Second, the review deliberately focused on SSA. Even though the region has predominantly low- to middle-income countries, findings may not
necessarily be generalizable to other low- and middle-income
countries outside this context. Relatedly, across the different
countries in SSA, there is diversity in aspects such as language, religious and cultural practices which may make the
results ungeneralizable to some communities within the
region. Lastly, the review search strategy was biased as only
publications in English were considered. It may be that we left
out important work reported in a language other than English.

3.9 | Implications of the findings for future
research, policy and practice
The limitations notwithstanding, this study has important
implications for future research, policy and practice. There is a
need to invest in mental health awareness as one of the primary prevention strategies aiming at preventing the occurrence of CMDs at high rates among YLWH in SSA. This can
entail psychoeducating YLWH about CMDs, that is what they
are, the signs and symptoms, when and where to seek help,
and providing them with self-help tips or quick guides through
forums such as peer-to-peer meetings. The high burden of
CMDs in YLWH from SSA highlights the urgent need to test
youth-friendly psychological and psychosocial interventions
that address CMDs faced by African youths living with HIV.
Adaptation of available interventions such as those identified
in a scoping review by Okonji et al. [105] may be a good starting point. The high burden also calls for the integration of
mental healthcare into the existing HIV care packages offered
to YLWH in this setting. Successful integration requires training of primary health care personnel at the HIV clinics on how
to manage CMDs (using, e.g. the World Health Organization’s
mhGAP intervention guide [106]), adequate infrastructure
68
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(0.10 to 0.59)
NR

NR

NR

0.93 ( 1.74 to 0.11)

-Satisfaction with
physical appearance:

1.77 ( 3.15 to

-No death in the family:

Protective
indicators

Psychosocial correlates

NR

NR

NR

NR

NR

Risk
indicators

Protective
indicators

(2.74)

0.001

Higher CD4
count:

NR

NR

NR

-No immune
suppression:
2.58
( 4.29
to 0.87)

HIV-related
correlates

AOR, Adjusted odds ratio; APR, Adjusted prevalence ratio; ART, Antiretroviral therapy; CD4, Cluster of Differentiation-4; CI, Confidence interval; MR, Mean ratio; NR, None reported; Se, Standard error; t, t statistic; b, Beta coefficients (adjusted).

NR

0.41)

-Rural residence: 0.61
(0.39 to 0.96)

to

2.38 ( 4.35

-Not being in a

-Fewer years of

to 5.98)

-Not failing a school
term/class: 1.46
( 2.76 to 0.17)

Protective
indicators

-Female sex:
2.13 (0.82
to 3.43)

Lwidiko et al.,
2018 [82]

b (95% CI)

Depressive
symptoms

Kim et al.,
2015 [28]

Risk indicators

Outcome

Measure of
effect
(precision)

Sociodemographic correlates

Author, year

Table 2.
4. (Continued)
(Continued)
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symptoms

symptoms
Anxiety

Anxiety

symptoms

Anxiety

symptoms

Anxiety

symptoms

Anxiety

Outcome

effect

APR (95% CI)

b (95% CI)

AOR (95% CI)

b (Se)

b (Se)

(precision)

NR

NR

NR

NR

NR

indicators

Risk

0.18

NR

NR

group = 0.19 (0.06 to 0.56)

13 to 15 years age
group vs. 16 to 19 years

to 0.37)

age group = 0.05 (0.01

group vs. 16 to 19 years

10 to 12 years age

-Younger age:

health:
(0.08)

-Better overall

NR

Protective indicators

Sociodemographic correlates

(0.44 to 1.01)
NR

-Stressful life events: 0.72

2.74 (1.09 to 6.85)

-History of physical violence:

(0.08)

0.02 (0.01)
-Anticipated stigma: 0.30

-Poor parental monitoring:

(0.02)

-Bullying victimisation: 0.15

(0.34)

-History of sexual abuse: 1.08

1.17 (0.19)

(0.07)
-Past year emotional abuse:

-Internalized stigma: 0.54

NR

Risk indicators

0.06 (0.02)

0.16

to 0.71)

-Higher social support: 0.30 (0.13

NR

NR

0.43 (0.14)

-Positive parenting: 0.05 (0.01)
-Access to clinic support group:

-Self-efficacy:

(0.06)

-Higher social support:

Protective indicators

Psychosocial correlates

APR, Adjusted prevalence ratio; ART, Antiretroviral therapy; CI, Confidence interval; NR, Not reported; Se, Standard error; b, Beta coefficients (adjusted).

West et al.
(2018) [58]

(2019) [66]

Hoare et al.

2020 [78]

Haas et al.,

(2018) [69]

Boyes et al.

(2018) [68]

Besthorn et al.

Author (year)

Measure of

Table 5. Sociodemographic, psychosocial and HIV-related correlates of anxiety symptoms among young people living with HIV from SSA

NR

NR

NR

effects: 0.51
(0.17)

-ART side

NR

indicators

Risk

NR

NR

NR

NR

NR

indicators

Protective

HIV-related correlates
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(including the availability of psychotropic medication), followed
by regular supervision and support from mental health specialists using a task-shifting approach [107,108].
Many of the included studies were cross-sectional in design,
did not compare the burden of CMDs between YLWH and
their uninfected peers, and focused more on depression than
anxiety. Alternative study designs that ascertain causal relationships are recommended for future investigations of factors
associated with CMDs among YLWH in SSA. Where feasible,
future studies seeking to understand CMDs in YLWH should
include an appropriate comparison group of HIV-negative
peers to clearly describe the burden. Finally, more research
on anxiety among YLWH from SSA is needed. Currently, this
data remains limited.

ABBREVIATIONS
ART, antiretroviral therapy; CASI-5, child and adolescent symptom inventory –
fifth edition; CD4, cluster of differentiation-4; CMDs, common mental disorders; DSM, diagnostic and statistical manual of mental disorders; ICD-10,
international classification of diseases – tenth edition; MINI-KID, mini internatonal neuropsychiatric interview for children and adolescents; PRISMA, preferred reporting items for systematic reviews and meta-analysis; PROSPERO,
the international prospective register of systematic reviews; SSA, sub-Saharan
Africa; YI-4R, Youth inventory – fourth revision; YLWH, young people living
with HIV.
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According to this review, the prevalence of CMDs in YLWH
from SSA is substantially high despite the wide variation of
reported estimates. From studies that recruited a comparison
group of HIV-negative peers, it appears YLWH are at a higher
risk of experiencing CMDs particularly depressive symptoms,
but more comparative research is needed to draw definite
conclusions. The mental health experience of YLWH in SSA is
not any different compared to that of YLWH from other settings, all are reporting high rates of CMDs. However, some of
the factors associated with CMDs among YLWH in SSA are
context-specific and may require contextualized intervention
approaches. YLWH at an elevated risk of CMDs in SSA such
as females, older youths, those with fewer schooling years,
with a history of sexual abuse, reporting ART adherence
issues, being bullied or experiencing HIV-related stigma may
benefit from early management or referral for treatment using
a stepped care approach [109] if at least targeted screening
for CMDs is done at the youth HIV clinics. Social support may
lower the risk for CMDs among YLWH in SSA and can be an
important component to consider when designing youthfriendly intervention packages for YLWH with comorbid
CMDs.
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